Actively Recruiting

Phase 3
Age: 75Years +
MALE
Healthy Volunteers
NCT05448547

Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer

Led by Sven Löffeler · Updated on 2025-07-01

980

Participants Needed

18

Research Sites

738 weeks

Total Duration

On this page

Sponsors

S

Sven Löffeler

Lead Sponsor

O

Oslo University Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

It is currently unclear if immediate curative treatment (radiotherapy or surgery) of high-risk prostate cancer without metastasis in older men (\>=75 years) generates the same survival benefits as in younger patients or if the harms/ side-effects of immediate curative treatment outweigh the benefits. In this study the investigators randomize older patients with high-risk, non-metastatic high-risk prostate cancer to either immediate curative therapy or to conservative, more problem-oriented therapy to investigate if immediate curative treatment prolongs life, improves quality of life and is cost-effective.

CONDITIONS

Official Title

Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer

Who Can Participate

Age: 75Years +
MALE
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Participant must be 75 years of age or older, at the time of signing the informed consent.
  • Participants who are healthy as determined by medical evaluation and geriatric G8/ miniCOGTM evaluation (G8: Fit, score >14, or reversibly frail; miniCOGTM: score >2)
  • Diagnosed with prostate cancer within 6 months with one or both of the following: Gleason grade 8-10 (ISUP group 4 and 5) with tumor palpable or visible on MRI (PIRADS 4 or 5), or locally advanced prostate cancer (T3 or T4) confirmed by clinical or radiological exam
  • Able to read, understand and fill in health-related quality of life questionnaires
  • Male
  • Capable of giving signed informed consent and complying with study requirements
Not Eligible

You will not qualify if you...

  • Dementia or unable to consent
  • Prior radiation to the pelvis
  • Hormone therapy for more than 3 months before randomization
  • Lymph node metastasis (N1) on MRI, CT or PSMA-PET CT
  • Distant metastasis (M1) on MRI, CT, bone scan or PSMA-PET CT
  • Disabled or severe comorbidity identified by G8 screening
  • Unable to read, understand or fill out health-related quality of life questionnaires

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 18 locations

1

Rigshospital

Copenhagen, Denmark

Actively Recruiting

2

Esbjerg and Grindsted Hospital

Esbjerg, Denmark

Actively Recruiting

3

Odense University Hospital

Odense, Denmark

Actively Recruiting

4

Helsinki University Hospital

Helsinki, Finland, 00029

Actively Recruiting

5

Tampere University Hospital

Tampere, Finland

Actively Recruiting

6

Turku University Hospital

Turku, Finland, 20520

Actively Recruiting

7

Sunmøre Hospital Trust

Ålesund, Møre og Romsdal, Norway

Actively Recruiting

8

Oslo University Hospital

Oslo, Oslo, Norway

Actively Recruiting

9

Stavanger University Hospital

Stavanger, Rogaland, Norway

Actively Recruiting

10

Sørlandet Hospital Trust

Kristiansand, Sørlandet, Norway, 4604

Actively Recruiting

11

Telemark Hospital Trust

Skien, Telemark, Norway, 3710

Actively Recruiting

12

St. Olavs Hospital

Trondheim, Trøndelag, Norway, 7006

Actively Recruiting

13

Vestfold Hospital Trust (Hospital of Vestfold)

Tønsberg, Vestfold, Norway, 3103

Actively Recruiting

14

Vestre Viken Hospital Trust

Drammen, Norway, 3004

Actively Recruiting

15

Innlandet Hospital Trust

Hamar, Norway

Actively Recruiting

16

Akerhus University Hospital

Lørenskog, Norway, 1478

Actively Recruiting

17

University Hospital of Northern Norway

Tromsø, Norway

Actively Recruiting

18

Capio Saint Göran's Hospital

Stockholm, Sweden, 11219

Actively Recruiting

Loading map...

Research Team

S

Sven Loffeler, MD, PhD

CONTACT

E

Erik S Haug, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here